市場調査レポート

商品コード

1561427

ペット用がん治療薬の市場レポート：療法、動物タイプ、がんタイプ、エンドユーザー、地域別、2024年～2032年

Pet Cancer Therapeutics Market Report by Therapy, Animal Species, Cancer Type, End User, and Region 2024-2032

出版日: 2024年09月10日
発行: IMARC
ページ情報: 英文 147 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 430,566円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcelの印刷は一度のみ可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (5 User License)

USD 3,999 574,136円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcelの印刷は可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 717,706円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等の編集は可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

ペット用がん治療薬の市場の世界市場規模は2023年に2億9,520万米ドルに達しました。今後、IMARC Groupは、市場は2032年までに6億3,590万米ドルに達し、2024年から2032年の間に8.5％の成長率（CAGR）を示すと予測しています。ペットの飼育率および人間と動物の絆の増加、獣医学および研究の進歩、ペット用がん治療薬の利用可能性および利点に関する認知度の向上は、市場を推進する主な要因の一部です。

ペット用がん治療薬は、動物、特に犬や猫のがんを診断、治療、管理するために設計された特殊な治療法や薬剤です。人間のがん治療と同様に、これらの治療薬には化学療法、放射線療法、免疫療法、標的療法、緩和ケアなどが含まれます。獣医腫瘍専門医は、ペットのさまざまな種類のがんに対処し、生活の質を向上させるために、これらの治療を行っています。獣医学が進歩するにつれて、ペットのがん治療薬の利用可能性と有効性が高まり、飼い主はがんと診断された最愛の動物のために包括的で思いやりのあるケアを利用できるようになった。

ペットの飼い主の間では、ペットの飼育や人間と動物の絆の増加により、動物の仲間の健康を確保するために、がん治療薬を含む先進医療への投資意欲が高まっており、予測期間中の市場の成長を刺激すると思われます。さらに、診断能力の向上と寿命の延長に起因するペットのがん有病率の増加が、効果的で専門的な治療に対する需要を増大させています。これとは別に、よりターゲットを絞った革新的なペット用がん治療法の開発など、獣医腫瘍学および研究における数々の進歩が、市場成長の触媒となっています。さらに、ペットのがん治療薬の利用可能性と利点に関する飼い主の意識の高まりは、早期発見と介入につながり、市場成長を促進しています。さらに、専門の獣医腫瘍学センターの設立や、獣医と人間の腫瘍学者間の協力関係の高まりにより、ペットがん治療へのアクセスや専門知識が向上していることも、市場成長に寄与しています。

ペット用がん治療薬の市場動向/促進要因：

ペット飼育の増加と人と動物の絆

ペット飼育の増加と人と動物の絆の強化は、ペット用がん治療薬市場の重要な促進要因となっています。ペットを生活に迎え入れる家庭が増えるにつれ、コンパニオンアニマルは大切な家族の一員とみなされるようになった。このような感情的なつながりは、飼い主の間に、毛皮で覆われた仲間の幸福と健康を保証するという深い責任感を育みます。その結果、ペットの飼い主の間では、病気と闘い、ペットの生活の質を高めるために、高度ながん治療に投資しようという意欲が高まっています。ペットの飼い主は、ペットにとって最良の治療を求めており、その結果、ペットの苦痛を和らげ、寿命を延ばすことができる効果的ながん治療薬への需要が高まっています。

獣医腫瘍学の進歩

獣医腫瘍学の分野は、技術の進歩と研究の飛躍的進歩により、近年目覚ましい進歩を遂げています。診断技術の向上により、早期かつ正確ながんの発見が可能になり、獣医師はタイムリーな治療を開始できるようになった。さらに、ペットのがん生物学に対する理解が深まったことで、標的療法、免疫療法、新規治療法への扉が開かれました。獣医がん専門医は現在、がん治療のツールボックスを拡大し、それぞれのペット特有の状態に合わせた個別化治療計画の策定を容易にしています。このような進歩は、愛する動物のがん診断に直面する飼い主に希望を与え、先進的で効果的ながん治療を模索し、選択するよう促します。

拡大する動物医療費

ペットが単なる動物の仲間から大切な家族の一員へと認識されるようになったことで、動物医療への支出パターンが顕著に変化しています。今日、ペットの飼い主は、ペットの幸福と長寿を確保するために、これまで以上に多額の財源を割くことを厭わなくなっています。利用可能ながん治療の選択肢に対する認識の高まりと、可能な限り最良の治療を提供したいという願望が、ペットのがん治療薬への支出増加の原動力となっています。飼い主は、病気と闘い、毛皮で覆われた仲間の全体的な健康と幸福を向上させるために、最新かつ最も効果的ながん治療に投資することを厭わないです。このような獣医学的ヘルスケアへの支出の急増は、研究、技術革新、ペット用の高度ながん治療法の開発の機会を生み出し、ペット用がん治療薬の市場をさらに推進します。

北米
- 米国
- カナダ
アジア太平洋地域
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
中東・アフリカ
- 市場動向
- 市場内訳：国別
- 市場予測

第11章 SWOT分析

概要
強み
弱み
機会
脅威

第12章バリューチェーン分析

第13章ポーターのファイブフォース分析

概要
買い手の交渉力
供給企業の交渉力
競合の程度
新規参入業者の脅威
代替品の脅威

第14章価格分析

第15章競合情勢

市場構造
主要企業
主要企業のプロファイル
- AB Science
- Boehringer Ingelheim International GmbH
- Elanco Animal Health Incorporated
- ELIAS Animal Health LLC
- Karyopharm Therapeutics
- Pfizer Inc.
- Regeneus Ltd.
- Rhizen Pharmaceuticals AG
- Torigen Pharmaceuticals Inc.
- VetDC Inc.
- Virbac
- Zoetis Inc.

図表

List of Figures

Figure 1: Global: Pet Cancer Therapeutics Market: Major Drivers and Challenges
Figure 2: Global: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018-2023
Figure 3: Global: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 4: Global: Pet Cancer Therapeutics Market: Breakup by Therapy (in %), 2023
Figure 5: Global: Pet Cancer Therapeutics Market: Breakup by Animal Species (in %), 2023
Figure 6: Global: Pet Cancer Therapeutics Market: Breakup by Cancer Type (in %), 2023
Figure 7: Global: Pet Cancer Therapeutics Market: Breakup by End User (in %), 2023
Figure 8: Global: Pet Cancer Therapeutics Market: Breakup by Region (in %), 2023
Figure 9: Global: Pet Cancer Therapeutics (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 10: Global: Pet Cancer Therapeutics (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 11: Global: Pet Cancer Therapeutics (Radiation Therapy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 12: Global: Pet Cancer Therapeutics (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 13: Global: Pet Cancer Therapeutics (Immunotherapy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 14: Global: Pet Cancer Therapeutics (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 15: Global: Pet Cancer Therapeutics (Combination Therapy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 16: Global: Pet Cancer Therapeutics (Combination Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 17: Global: Pet Cancer Therapeutics (Other Therapies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 18: Global: Pet Cancer Therapeutics (Other Therapies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 19: Global: Pet Cancer Therapeutics (Cats) Market: Sales Value (in Million US$), 2018 & 2023
Figure 20: Global: Pet Cancer Therapeutics (Cats) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 21: Global: Pet Cancer Therapeutics (Dogs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 22: Global: Pet Cancer Therapeutics (Dogs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 23: Global: Pet Cancer Therapeutics (Other Animal Species) Market: Sales Value (in Million US$), 2018 & 2023
Figure 24: Global: Pet Cancer Therapeutics (Other Animal Species) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 25: Global: Pet Cancer Therapeutics (Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
Figure 26: Global: Pet Cancer Therapeutics (Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 27: Global: Pet Cancer Therapeutics (Mast Cell Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 28: Global: Pet Cancer Therapeutics (Mast Cell Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 29: Global: Pet Cancer Therapeutics (Melanoma) Market: Sales Value (in Million US$), 2018 & 2023
Figure 30: Global: Pet Cancer Therapeutics (Melanoma) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 31: Global: Pet Cancer Therapeutics (Mammary and Squamous Cell Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 32: Global: Pet Cancer Therapeutics (Mammary and Squamous Cell Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 33: Global: Pet Cancer Therapeutics (Other Cancer Types) Market: Sales Value (in Million US$), 2018 & 2023
Figure 34: Global: Pet Cancer Therapeutics (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 35: Global: Pet Cancer Therapeutics (Veterinary Hospitals and Clinical Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 36: Global: Pet Cancer Therapeutics (Veterinary Hospitals and Clinical Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 37: Global: Pet Cancer Therapeutics (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 38: Global: Pet Cancer Therapeutics (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 39: Global: Pet Cancer Therapeutics (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 40: Global: Pet Cancer Therapeutics (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 41: Global: Pet Cancer Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
Figure 42: Global: Pet Cancer Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 43: North America: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 44: North America: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 45: United States: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 46: United States: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 47: Canada: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 48: Canada: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 49: Asia-Pacific: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 50: Asia-Pacific: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 51: China: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 52: China: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 53: Japan: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 54: Japan: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 55: India: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 56: India: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 57: South Korea: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 58: South Korea: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 59: Australia: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 60: Australia: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 61: Indonesia: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 62: Indonesia: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 63: Others: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 64: Others: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 65: Europe: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 66: Europe: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 67: Germany: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 68: Germany: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 69: France: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 70: France: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 71: United Kingdom: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 72: United Kingdom: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 73: Italy: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 74: Italy: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 75: Spain: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 76: Spain: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 77: Russia: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 78: Russia: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 79: Others: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 80: Others: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 81: Latin America: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 82: Latin America: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 83: Brazil: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 84: Brazil: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 85: Mexico: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 86: Mexico: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 87: Others: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 88: Others: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 89: Middle East and Africa: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
Figure 90: Middle East and Africa: Pet Cancer Therapeutics Market: Breakup by Country (in %), 2023
Figure 91: Middle East and Africa: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 92: Global: Pet Cancer Therapeutics Industry: SWOT Analysis
Figure 93: Global: Pet Cancer Therapeutics Industry: Value Chain Analysis
Figure 94: Global: Pet Cancer Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Pet Cancer Therapeutics Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Pet Cancer Therapeutics Market Forecast: Breakup by Therapy (in Million US$), 2024-2032
Table 3: Global: Pet Cancer Therapeutics Market Forecast: Breakup by Animal Species (in Million US$), 2024-2032
Table 4: Global: Pet Cancer Therapeutics Market Forecast: Breakup by Cancer Type (in Million US$), 2024-2032
Table 5: Global: Pet Cancer Therapeutics Market Forecast: Breakup by End User (in Million US$), 2024-2032
Table 6: Global: Pet Cancer Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 7: Global: Pet Cancer Therapeutics Market: Competitive Structure
Table 8: Global: Pet Cancer Therapeutics Market: Key Players

Product Code: SR112024A4472

The global pet cancer therapeutics market size reached US$ 295.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 635.9 Million by 2032, exhibiting a growth rate (CAGR) of 8.5% during 2024-2032. The increasing pet ownership rates and human-animal bond, advancements in veterinary medicine and research, and growing awareness about the availability and benefits of pet cancer therapeutics are some of the major factors propelling the market.

Pet cancer therapeutics are specialized medical treatments and drugs designed to diagnose, treat, and manage cancer in animals, particularly in dogs and cats. Similar to cancer treatments in humans, these therapeutics may include chemotherapy, radiation therapy, immunotherapy, targeted therapies, and palliative care. Veterinary oncologists administer these therapies to address various types of cancer in pets and improve their quality of life. As advancements in veterinary medicine continue, the availability and effectiveness of pet cancer therapeutics have increased, allowing pet owners to access comprehensive and compassionate care for their beloved animal companions diagnosed with cancer.

The rising willingness among pet owners to invest in advanced medical treatments, including cancer therapeutics, to ensure the well-being of their animal companions due to the increasing pet ownership and human-animal bond, will stimulate the growth of the market during the forecast period. Moreover, the growing prevalence of cancer in pets, owing to improved diagnostic capabilities and prolonged lifespan has augmented the demand for effective and specialized treatments. Apart from this, numerous advancements in veterinary oncology and research, including the development of more targeted and innovative cancer therapies for pets, have catalyzed the market growth. Additionally, the heightening awareness among pet owners about the availability and benefits of pet cancer therapeutics has led to early detection and intervention, propelling the market growth. Furthermore, the establishment of specialized veterinary oncology centers and the rising collaborations between veterinary and human oncologists that improve the accessibility and expertise in pet cancer care are contributing to the market growth.

Pet Cancer Therapeutics Market Trends/Drivers:

Increasing pet ownership and human-animal bond

The rise in pet ownership and the strengthening human-animal bond have become significant drivers in the market for pet cancer therapeutics. As more households welcome pets into their lives, these companion animals are widely considered cherished family members. This emotional connection fosters a deep sense of responsibility among pet owners to ensure the well-being and health of their furry companions. Consequently, there is a growing willingness among pet owners to invest in advanced cancer treatments to combat the disease and enhance the quality of life for pets. Pet owners seek the best possible care for their pets, leading to an increased demand for effective cancer therapeutics that can alleviate suffering and prolong their pets' lives.

Advancements in veterinary oncology

The field of veterinary oncology has witnessed remarkable progress in recent years, owing to technological advancements and research breakthroughs. Improved diagnostic techniques enable early and accurate cancer detection, empowering veterinarians to initiate timely treatment. Moreover, the rise in understanding of cancer biology in pets has opened doors to targeted therapies, immunotherapies, and novel treatment modalities. Veterinary oncologists now have an expanded toolbox of cancer treatments, facilitating the development of personalized care plans tailored to each pet's unique condition. These advancements instill hope in pet owners facing a cancer diagnosis for their beloved animals and encourage them to explore and opt for advanced and effective cancer therapies.

Growing veterinary healthcare expenditure

The changing perception of pets from mere animal companions to valued family members has led to a notable shift in spending patterns on veterinary healthcare. Pet owners today are more willing than ever to allocate substantial financial resources to ensure their pets' well-being and longevity. The growing awareness of available cancer treatment options and the desire to provide the best possible care have driven the increase in expenditure on pet cancer therapeutics. Owners are willing to invest in the latest and most effective cancer treatments to combat the disease and improve the overall health and happiness of their furry companions. This surge in veterinary healthcare spending further propels the pet cancer therapeutics market, creating opportunities for research, innovation, and the development of advanced cancer treatment options for pets.

Pet Cancer Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global pet cancer therapeutics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on therapy, animal species, cancer type and end user.

Breakup by Therapy:

Chemotherapy
Radiation Therapy
Immunotherapy
Combination Therapy
Others

Chemotherapy dominates the market

The report has provided a detailed breakup and analysis of the market based on the therapy. This includes chemotherapy, radiation therapy, immunotherapy, combination therapy, and others. According to the report, chemotherapy represented the largest segment.

Chemotherapy is widely used as a standard treatment for various types of pet cancers. As a potent and systematic approach, chemotherapy targets rapidly dividing cancer cells, inhibiting their growth and spread. Its ability to treat a wide range of cancers, including lymphoma, mast cell tumors, and osteosarcoma, makes it a versatile and essential therapeutic option for veterinary oncologists.

Moreover, advancements in veterinary medicine have led to the development of more targeted and less toxic chemotherapy regimens, reducing adverse effects and improving the overall quality of life for pets undergoing treatment. The increasing prevalence of pet cancer cases, coupled with the growing awareness among pet owners about available treatment options, further contributes to the expansion of the chemotherapy segment.

Breakup by Animal Species:

Cats
Dogs
Others

Dogs hold the largest share in the market

A detailed breakup and analysis of the market based on the animal species has also been provided in the report. This includes cats, dogs, and others. According to the report, dogs accounted for the largest market share.

Dogs have a higher susceptibility to various types of cancers, mirroring human conditions. As a popular companion animal, dogs are commonly affected by cancers such as lymphoma, melanoma, and mammary tumors, among others. The similarities in cancer biology and tumor types between dogs and humans make dogs valuable models for studying cancer treatments, leading to advancements in therapeutic approaches that benefit both species. Veterinary oncology research conducted in dogs has resulted in the development of targeted therapies, immunotherapies, and novel treatment modalities that can be translated to human medicine. Furthermore, the strong emotional bond between pet owners and their dogs fosters a willingness to invest in their healthcare, including cancer treatments, thus driving the demand for effective pet cancer therapeutics.

Breakup by Cancer Type:

Lymphoma
Mast Cell Cancer
Melanoma
Mammary and Squamous Cell Cancer
Others

Mast cell cancer represents the most popular type of cancer

The report has provided a detailed breakup and analysis of the market based on the cancer type. This includes lymphoma, mast cell cancer, melanoma, mammary and squamous cell cancer, and others. According to the report, mast cell cancer represented the largest segment.

Mast cell tumors are one of the most common skin cancers in dogs, affecting various breeds and age groups. Their diverse behavior and variable response to treatments necessitate specialized therapeutics for effective management. Veterinary oncologists are continually researching and developing targeted therapies and immunotherapies specifically tailored to combat mast cell cancer. As a result, advancements in pet cancer therapeutics for mast cell tumors benefit dogs as well as contribute to the broader understanding and treatment of mast cell-related conditions in humans. The increasing awareness among pet owners about the need for early detection and comprehensive treatment options further drives the demand for innovative and efficient pet cancer therapeutics.

Breakup by End User:

Veterinary Hospitals and Clinical Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Veterinary hospitals and clinical pharmacies account for the largest market share

The report has provided a detailed breakup and analysis of the market based on the end-user. This includes veterinary hospitals and clinical pharmacies, retail pharmacies, online pharmacies, and others. According to the report, veterinary hospitals and clinical pharmacies represented the largest segment.

Veterinary hospitals and clinical pharmacies play a crucial role in driving the pet cancer therapeutics market by serving as key distribution and treatment centers for specialized pet cancer drugs and therapies. These institutions provide a centralized platform for pet owners to access a wide range of cancer treatments, including chemotherapy agents, targeted therapies, and immunotherapies. Veterinary hospitals collaborate with pharmaceutical companies and research institutions to stay updated on the latest advancements in pet cancer therapeutics, offering cutting-edge treatment options to their patients. Clinical pharmacies within these facilities ensure accurate drug dispensing and administration, adhering to precise dosages and treatment protocols. Their expertise in handling pet cancer therapeutics and providing personalized care contributes to improved treatment outcomes and enhances pet owners' confidence in seeking optimal cancer care for their beloved animal companions, ultimately driving the growth of the pet cancer therapeutics market.

Breakup by Region:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and Others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and Others) Latin America (Brazil, Mexico and Others), Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest share in the market since the region has a high prevalence of pet ownership, and there is a strong bond between pet owners and their animals, leading to a greater willingness to invest in their healthcare, including cancer treatment. North America is also at the forefront of advancements in veterinary medicine and oncology research, resulting in the development of innovative and targeted pet cancer therapeutics. Veterinary hospitals and research institutions in the region collaborate closely with pharmaceutical companies to conduct clinical trials and introduce cutting-edge treatments to the market. Additionally, the presence of well-established veterinary healthcare infrastructure and a growing trend of personalized pet care contribute to the demand for specialized and effective cancer therapies. These factors collectively drive the growth of the market for pet cancer therapeutics in North America, making it a leading region in the industry.

Competitive Landscape:

The market is experiencing steady growth in recent years as various key players are focusing on the development of targeted therapies and immunotherapies tailored to specific types of pet cancers, aiming to enhance treatment effectiveness and reduce side effects. Numerous advancements in precision medicine by leading players have led to the identification of genetic and molecular biomarkers, allowing for personalized treatment approaches. Additionally, novel drug delivery methods, such as nanoparticles and liposomes, are being explored by manufacturers to improve drug stability and enhance tumor penetration. The integration of emerging technologies like artificial intelligence (AI) and machine learning (ML) in pet cancer research is revolutionizing data analysis and accelerating drug discovery processes. We also expect the market to witness new entrants, consolidation of product portfolios, rise in research and development (R&D) initiatives, and increased strategic collaborations to drive healthy competition within the pet cancer therapeutics domain.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AB Science
Boehringer Ingelheim International GmbH
Elanco Animal Health Incorporated
ELIAS Animal Health LLC
Karyopharm Therapeutics
Pfizer Inc.
Regeneus Ltd.
Rhizen Pharmaceuticals AG
Torigen Pharmaceuticals Inc.
VetDC Inc.
Virbac
Zoetis Inc.

Recent Developments:

In July 2023, Boehringer Ingelheim International GmbH, a leading pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for its innovative product, NexGard PLUS. This groundbreaking advancement in pet healthcare introduces a chewable tablet specifically designed to safeguard dogs from both internal and external parasites. The tablet contains a powerful combination of active ingredients, including afoxolaner, moxidectin, and pyrantel, which work synergistically to provide comprehensive protection against common parasitic threats.
In Dec 2022, Elanco Animal Health Incorporated, a prominent animal health company, announced a groundbreaking achievement with the FDA approval of Bexacat (bexagliflozin tablets). Bexacat marks a significant milestone as the first-of-its-kind oral treatment option for feline diabetes. This pioneering medication introduces a novel approach to managing diabetes in cats, addressing an unmet medical need in the veterinary industry. Bexacat, formulated as easily administered tablets, offers a promising solution for feline diabetes management, providing veterinarians and pet owners with an effective and convenient alternative to traditional insulin injections.
In Nov 2021, ELIAS Animal Health LLC, a leading biotechnology company specializing in cancer therapeutics for pets, announced a significant development in the field of oncolytic virotherapy. The company has successfully obtained an exclusive in-license from Genelux Corporation for their cutting-edge Oncolytic Vaccinia Virus Treatment. This groundbreaking treatment utilizes a modified vaccinia virus to target and destroy cancer cells in pet animals. By leveraging the virus's inherent ability to replicate and infect cancer cells while sparing healthy tissues, this therapy offers a novel approach to combat various types of pet cancers.

Key Questions Answered in This Report

1. What was the size of the global pet cancer therapeutics market in 2023?
2. What is the expected growth rate of the global pet cancer therapeutics market during 2024-2032?
3. What are the key factors driving the global pet cancer therapeutics market?
4. What has been the impact of COVID-19 on the global pet cancer therapeutics market?
5. What is the breakup of the global pet cancer therapeutics market based on the therapy?
6. What is the breakup of the global pet cancer therapeutics market based on thej animal species?
7. What is the breakup of the global pet cancer therapeutics market based on cancer type?
8. What is the breakup of the global pet cancer therapeutics market based on the end user?
9. What are the key regions in the global pet cancer therapeutics market?
10. Who are the key players/companies in the global pet cancer therapeutics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Pet Cancer Therapeutics Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Therapy

6.1 Chemotherapy
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Radiation Therapy
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Immunotherapy
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Combination Therapy
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast

7 Market Breakup by Animal Species

7.1 Cats
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Dogs
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Others
- 7.3.1 Market Trends
- 7.3.2 Market Forecast

8 Market Breakup by Cancer Type

8.1 Lymphoma
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Mast Cell Cancer
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Melanoma
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Mammary and Squamous Cell Cancer
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
8.5 Others
- 8.5.1 Market Trends
- 8.5.2 Market Forecast

9 Market Breakup by End User

9.1 Veterinary Hospitals and Clinical Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Online Pharmacies
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia-Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 AB Science
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
- 15.3.2 Boehringer Ingelheim International GmbH
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 SWOT Analysis
- 15.3.3 Elanco Animal Health Incorporated
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
- 15.3.4 ELIAS Animal Health LLC
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
- 15.3.5 Karyopharm Therapeutics
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
- 15.3.6 Pfizer Inc.
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
  - 15.3.6.4 SWOT Analysis
- 15.3.7 Regeneus Ltd.
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
- 15.3.8 Rhizen Pharmaceuticals AG
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
- 15.3.9 Torigen Pharmaceuticals Inc.
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
- 15.3.10 VetDC Inc.
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
- 15.3.11 Virbac
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio
  - 15.3.11.3 Financials
  - 15.3.11.4 SWOT Analysis
- 15.3.12 Zoetis Inc.
  - 15.3.12.1 Company Overview
  - 15.3.12.2 Product Portfolio
  - 15.3.12.3 Financials
  - 15.3.12.4 SWOT Analysis

ペット用がん治療薬の市場レポート：療法、動物タイプ、がんタイプ、エンドユーザー、地域別、2024年～2032年

Pet Cancer Therapeutics Market Report by Therapy, Animal Species, Cancer Type, End User, and Region 2024-2032

ペット用がん治療薬の市場動向/促進要因：

目次

第1章 序文

第2章 調査範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のペット用がん治療薬市場

第6章 市場内訳：療法

第7章 市場内訳：動物タイプ別

第8章 市場内訳：がんタイプ別

第9章 市場内訳：エンドユーザー別

第10章 市場内訳：地域別

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢